Research programme: selective androgen receptor inhibitors - GTx

Drug Profile

Research programme: selective androgen receptor inhibitors - GTx

Alternative Names: GTx-SARD; SARD - GTx; Selective androgen receptor degrader - GTx

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tennessee Research Foundation
  • Developer GTx
  • Class Antiandrogens; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Prostate cancer presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 15 Mar 2017 GTx plans a phase I trial for Prostate cancer (castration-resistant) in USA
  • 15 Mar 2017 GTx has patent protection for selective androgen receptor inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top